Biosig Instruments, Inc. v. Nautilus, Inc.
Decision Date | 27 April 2015 |
Docket Number | No. 2012–1289.,2012–1289. |
Citation | 114 U.S.P.Q.2d 1651,783 F.3d 1374 |
Parties | BIOSIG INSTRUMENTS, INC., Plaintiff–Appellant v. NAUTILUS, INC., Defendant–Appellee. |
Court | U.S. Court of Appeals — Federal Circuit |
Mark David Harris, Proskauer Rose LLP, New York, N.Y., argued for plaintiff-appellant. Also represented by Paul Milcetic, Villanova, PA; Todd Kupstas, Kessler Topaz Meltzer & Check, LLP, Radnor, PA; Daniel C. Mulveny, Kessler Topaz Meltzer & Check, LLP, Radnor, PA; John E. Roberts, Proskauer Rose LLP, Boston, MA.
John D. Vandenberg, Klarquist Sparkman, LLP, Portland, OR, argued for defendant-appellee. Also represented by James E. Geringer, Philip J. Warrick, Jeffrey S. Love.
Before NEWMAN, SCHALL, and WALLACH, Circuit Judges.
This case is before us on remand from the United States Supreme Court. Biosig Instruments, Inc. (“Biosig”) is the assignee of U.S. Patent No. 5,337,753 (“the '753 patent”), directed to a heart rate monitor associated with an exercise apparatus and/or exercise procedures. Biosig brought a patent infringement action against Nautilus, Inc. (“Nautilus”) in district court alleging that Nautilus infringed claims 1 and 11 of the '753 patent. After claim construction, Nautilus filed a motion for summary judgment seeking, in relevant portion, to have the '753 patent held invalid for indefiniteness. The district court granted Nautilus's motion, and Biosig appealed. This court found the claims at issue were not invalid for indefiniteness, and reversed and remanded for further proceedings. Nautilus petitioned for certiorari, and the Supreme Court vacated and remanded this court's decision. On remand, we maintain our reversal of the district court's determination that Biosig's patent claims are indefinite.
The facts of this case were recited in detail in this court's previous opinion and need not be repeated in full here. Nautilus, Inc. v. Biosig Instruments, Inc. (Nautilus I ), 715 F.3d 891, 898 (Fed.Cir.2013) In summary, the '753 patent is directed to a heart rate monitor that purports to improve upon the prior art by effectively eliminating “noise” signals during the process of detecting a user's heart rate. '753 patent col. 1 ll. 5–10. The '753 patent discloses an apparatus preferably mounted on exercise equipment that measures heart rates by, inter alia, processing electrocardiograph (“ECG”) signals from which electromyogram (“EMG”) signals are substantially removed. Id. col. 1. ll. 36–41. Claim 1 is representative and recites, in relevant part:
Id. col. 5 ll. 17–36 (emphases added).
Biosig sued Nautilus for infringement of the '753 patent in August 2004. After several reexamination proceedings, Biosig reinstituted a patent infringement action against Nautilus on October 8, 2010. On August 11, 2011, the district court conducted a Markman hearing, and on September 29, 2011, issued its order construing certain disputed claim terms. On November 10, 2011, Nautilus moved under Federal Rule of Civil Procedure 56 for summary judgment on two issues: infringement and invalidity for indefiniteness. On February 22, 2012, the district court granted Nautilus's motion, holding the ' 753 patent's “spaced relationship” term as recited in claim 1 was indefinite as a matter of law. The court did not decide the issue of infringement.
On appeal, this court reversed and remanded. Citing precedent, we stated that a claim is indefinite “only when it is ‘not amenable to construction’ or ‘insolubly ambiguous.’ ” Nautilus I, 715 F.3d at 898 (quoting Datamize, LLC v. Plumtree Software, Inc., 417 F.3d 1342, 1347 (Fed.Cir.2005) ). Under that standard, we determined the '753 patent survived indefiniteness review. Considering the “intrinsic evidence,” we found that it provided “certain inherent parameters of the claimed apparatus, which to a skilled artisan may be sufficient to understand the metes and bounds of ‘spaced relationship.’ ” Id. at 899.
The Supreme Court granted certiorari, ––– U.S. ––––, 134 S.Ct. 896, 187 L.Ed.2d 702 (2014), and, rejecting our “not amenable to construction or insolubly ambiguous” standard, vacated and remanded. Nautilus, Inc. v. Biosig Instruments, Inc. (Nautilus II ), ––– U.S. ––––, 134 S.Ct. 2120, 189 L.Ed.2d 37 (2014). In its decision, the Court articulated the standard to be applied: “[W]e hold that a patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty those skilled in the art about the scope of the invention.” Id. at 2124 (emphasis added).
This court has jurisdiction pursuant to 28 U.S.C. § 1295(a)(1) (2012).
A patent must “conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as [the] invention.”35 U.S.C. § 112 ¶ 2 (2006).1 A claim is invalid for indefiniteness if its language, when read in light of the specification and the prosecution history, “fail[s] to inform, with reasonable certainty, those skilled in the art about the scope of the invention.” Nautilus II, 134 S.Ct. at 2124. We review the district court's indefiniteness determination de novo. Interval Licensing LLC v. AOL, Inc., 766 F.3d 1364, 1370 (Fed.Cir.2014).
A patent is presumed valid under 35 U.S.C. § 282 and, “consistent with that principle, a [fact finder is] instructed to evaluate ... whether an invalidity defense has been proved by clear and convincing evidence.” Microsoft Corp. v. i4i Ltd. P'ship, ––– U.S. ––––, 131 S.Ct. 2238, 2241, 180 L.Ed.2d 131 (2011).
“In the face of an allegation of indefiniteness, general principles of claim construction apply.”
Enzo Biochem, Inc. v. Applera Corp., 599 F.3d 1325, 1332 (Fed.Cir.2010) (internal quotation marks and citation omitted). “In that regard, claim construction involves consideration of primarily the intrinsic evidence, viz., the claim language, the specification, and the prosecution history.” Id. Though the ultimate construction of a claim term is a legal question reviewed de novo, underlying factual determinations made by the district court based on extrinsic evidence are reviewed for clear error. Teva Pharm. USA, Inc. v. Sandoz, Inc., –––U.S. ––––, 135 S.Ct. 831, 842, ––– L.Ed.2d –––– (2015). In contrast, “when the district court reviews only evidence intrinsic to the patent (the patent claims and specifications, along with the patent's prosecution history), the judge's determination will amount solely to a determination of law, and the Court of Appeals will review that construction de novo.” Id. at 841.
When a “word of degree” is used, the court must determine whether the patent provides “some standard for measuring that degree.” Enzo Biochem, 599 F.3d at 1332 ; Seattle Box Co., Inc. v. Indus. Crating & Packing, Inc., 731 F.2d 818, 826 (Fed.Cir.1984). Recently, this court explained: Interval Licensing, 766 F.3d at 1370. Moreover, when a claim limitation is defined in “purely functional terms,” a determination of whether the limitation is sufficiently definite is “highly dependent on context (e.g., the disclosure in the specification and the knowledge of a person of ordinary skill in the relevant art area).” Halliburton Energy Servs., Inc. v. M–I LLC, 514 F.3d 1244, 1255 (Fed.Cir.2008).
Prior to the Supreme Court's decision in this case, a claim was indefinite when it was “insolubly ambiguous” or “not amenable to construction.” Datamize, 417 F.3d at 1347 (internal quotations and citations omitted). In Nautilus II, the Supreme Court observed that § 112, ¶ 2 requires “a delicate balance.” 134 S.Ct. at 2128 (quoting Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 731, 122 S.Ct. 1831, 152 L.Ed.2d 944 (2002) ). On one hand, the Court noted, the definiteness requirement must take into account the inherent limitations of language. “Some modicum of uncertainty,” the Court recognized, is the “ ‘price of ensuring the appropriate incentives for innovation.’ ” Id. (quoting Festo Corp., 535 U.S. at 741, 122 S.Ct. 1831 ). On the other hand, the Court explained, a patent must be precise enough to afford clear notice of what is claimed, thereby Id. at 2129 (internal quotation marks and citations omitted). The Court further explained the policy rationale: “absent a meaningful definiteness check ... patent applicants face powerful incentives to inject ambiguity into their claims.” Id.
Balancing these competing interests, the Supreme Court held that “[t]o determine the proper office of the definiteness command, ... we read § 112, ¶ 2 to require that a patent's claims, viewed in light of the specification and prosecution history, inform those skilled in the art about the...
To continue reading
Request your trial-
Card-Monroe Corp. v. Tuftco Corp.
...is that the patent apprise [ordinary-skilled artisans] of the scope of the invention." Biosig Instruments, Inc. v. Nautilus, Inc. , 783 F.3d 1374, 1381 (Fed. Cir. 2015) (citation omitted). Accordingly, this Court will "now steer by the bright star of ‘reasonable certainty,’ rather than the ......
-
Front Row Techs., LLC v. NBA Media Ventures, LLC, CIV 10–0433 JB/SCY
...or burdens involved in the process. The Federal Circuit has since cited Microsoft in its opinions. See Biosig Instruments, Inc. v. Nautilus, Inc. , 783 F.3d 1374, 1377 (Fed.Cir.2015) ("A patent is presumed valid under 35 U.S.C. § 282 and, consistent with that principle, a [fact finder is] i......
-
Veracode, Inc. v. Appthority, Inc.
...inform those skilled in the art about the scope of the invention with reasonable certainty." Id .; see Biosig Instruments, Inc. v. Nautilus, Inc. , 783 F.3d 1374, 1379–80 (Fed.Cir.2015)("reasonable certainty" is defined on a spectrum but is clearer than earlier indefiniteness standard). The......
-
3RD Eye Surveillance, LLC v. United States
...the court is now instructed to follow a "reasonable certainty" standard when constructing claims. Biosig Instruments, Inc. v. Nautilus, Inc., 783 F.3d 1374, 1380 (Fed. Cir. 2015), on remand from Nautilus II, 572 U.S. 898. The Federal Circuit has interpreted this new "bright star" standard a......
-
Delaware Judges Are Finding Patent Claims Indefinite Post-Nautilus
...star of 'reasonable certainty,' rather than the unreliable compass of 'insoluble ambiguity.'" Biosig Instruments, Inc. v. Nautilus, Inc., 783 F.3d 1374, 1379 (Fed. Cir. Nonetheless, the holding in Nautilus was recently cited by Judge Sue Robinson in the District of Delaware in finding the c......
-
Chapter §2.04 Claim Definiteness Requirement
...and maintaining its reversal of the district court's determination to the contrary. See Biosig Instruments, Inc. v. Nautilus, Inc., 783 F.3d 1374 (Fed. Cir. 2015) ("Nautilus III"). The facts and reasoning of Nautilus III are further examined infra §2.04[D][1] ("Representative Examples of De......
-
Case Comments
...electrodes that was neither infinitesimally small nor greater than the width of a user's hands. Biosig Instmts., Inc. v. Nautilus, Inc., 783 F.3d 1374, 114 U.S.P.Q.2d 1651 (Fed. Cir. 2015).PATENTS - INDUCEMENT "[L]iability for induced infringement can only attach if the defendant knew of th......
-
After Nautilus: The Tension Between the Inherent Lack of Clarity of Language and Notice Function of Patent Law
...quotation marks omitted). 10. 35 U.S.C. § 282(a); Nautilus , 134 S. Ct. at 2130–31 n.10. 11. Biosig Instruments, Inc. v. Nautilus, Inc., 783 F.3d 1374, 1382–84 (Fed. Cir. 2015). 12. Id. at 1382. 13. 838 F.3d 1224 (Fed. Cir. 2016). 14. Id. at 1235. 15. Id. at 1229–31. 16. Id. 17. Id. at 1231......
-
UNDERSTANDING NAUTILUS' REASONABLE-CERTAINTY STANDARD: REQUIREMENTS FOR LINGUISTIC AND PHYSICAL DEFINITENESS OF PATENT CLAIMS.
...does not suffer from indefiniteness."), vacated, 134 S. Ct. 2120 (2014), with Biosig Instruments, Inc. v. Nautilus, Inc. (Nautilus III), 783 F.3d 1374, 1376 (Fed. Cir.) ("[W]e maintain our reversal of the district court's determination that Biosig's patent claims are indefinite."), cert, de......